Deciphera Pharmaceuticals, Inc. (DCPH) announced the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorization for QINLOCK in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib.
The company said the QINLOCK approval was supported by efficacy results from the primary analysis of the pivotal phase 3 INVICTUS study in patients with advanced gastrointestinal stromal tumor and combined safety results from INVICTUS and the phase 1 study of QINLOCK.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.